Although 90% of those surveyed said they stand by their choice of treatment, one-third did not have enough information about the side effects of radiation, chemotherapy or surgery.

Patient outcomes don’t differ significantly across high- or low-cost hospitals, according to a study from Harvard and Yale researchers published in JAMA Network Open.

INFINITT North America, award–winning developer of enterprise image management solutions for healthcare, will be highlighting a next generation, AI-empowered PACS viewer at RSNA 2019.

The American College of Radiology (ACR) Data Science Institute (DSI) has created a new resource for radiology researchers: a full list of FDA-cleared AI algorithms related to medical imaging.  

This year’s competition brought out the best in a strong field. All entrants developed notably original breakthroughs in various aspects of medical imaging. And the winners never lost sight of the ultimate point of all the extra effort: improving patient care while increasing efficiencies and, wherever possible, cutting or at least containing costs. Now meet the best of the best. 

American counties hit hardest by the Great Recession saw a sharp increase in deaths from CVD and stroke that wasn’t mirrored in communities that experienced less economic distress, according to a new study.

Series of educational workshops designed to educate radiologists, administrators, technologists on the potential benefits of the latest breast cancer screening technology. 

The update arrives to coincide with flu season, when providers will start seeing increasing cases of respiratory illnesses. 

Hitachi’s newest CT solution, the SCENARIA View 128, has received FDA clearance and is now being installed at hospitals throughout the United States. Jason Miller, Hitachi’s executive director of radiology products, and Richard Pacenta, Hitachi’s executive director of sales, spoke with us about this exciting new solution and what the company has planned for RSNA 2019 in Chicago.

Humana has released the findings of its latest value-based care report, detailing how the company is continuing to move away from fee-for-service when it comes to their Medicare Advantage population.